Synthesis, Powder Diffraction Pattern, Crystal Structure Determination of the Pharmaceutical Co-Crystal of Levetiracetam and 3,5-Dinitrosalicylic Acid

Lingling Shi,Zhengguo Chen,Hany Kafafy,Zhaoxia Zhang,Guocheng Zhu,Juming Yao,Guoqing Zhang
DOI: https://doi.org/10.1017/s0885715623000374
IF: 2.544
2023-01-01
Powder Diffraction
Abstract:(S)-α-Ethyl-2-oxo-1-pyrrolidineacetamide (trade name levetiracetam), a derivative of piracetam, is used clinically as an add-on treatment for partial-onset seizures. In this study, we report the solid-state structure of a new drug co-crystal produced from levetiracetam and 3,5-dinitrosalicylic acid through cooling crystallization. This compound was further characterized by infrared spectroscopy, powder X-ray diffraction, and single-crystal X-ray diffraction. The new co-crystals show a 1:1 stoichiometry and crystallize in the monoclinic system, space group P21, with cell parameters: a = 9.7709(3) Å, b = 6.2202(2) Å, c = 14.7280(4) Å, α = 90°, β = 96.0340(10)°, γ = 90°, V = 890.16(5) Å3, and Z = 2. It is identified that hydrogen bonds are the main interactions between levetiracetam and 3,5-dinitrosalicylic acid, and the contribution of each hydrogen bond in maintaining the stability of the crystal structure was also quantified using Hirshfeld surface analysis.
What problem does this paper attempt to address?